(S)-4-Benzyl-2-(pyridin-2-yl)-4,5-dihydrooxazole, 98.0%, 100mg

2-(4-Fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole, 97%, 100mg

tert-Butyl (3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)amino)propyl)carbamate, 5g

2-Morpholinonicotinonitrile, 95.0%, 1g

tert-Butyl 6-((methylsulfonyl)oxy)-2-azaspiro[3.3]heptane-2-carboxylate, 97%, 100mg

5,5'-Sulfonyldiisophthalic acid, 95%, 1g

Analytical and precision scale Secura® Series Standard models, not certified, 0.01 g, 1100 g, 1102-1S

Imidazo[1,2-a]pyridine, 97.0%, 100g

GC capillary column ROTI®Cap-1701, 50 m, 0.32 mm, 0.50 µm, 1 Piece(s)

3-Formyl-1H-indazole-6-carboxylic acid, 95.0%, 1g

4,4,5,5-Tetramethyl-2-(4-((trifluoromethyl)sulfonyl)phenyl)-1,3,2-dioxaborolane, 97%, 500mg

Plan PLPHi 10x/0.25 phase contrast IOS infinity corrected objective

4-(Chloromethyl)pyridin-2-amine hydrochloride, 95.0%, 1g